Search clinical trials for: PF-3512676 Erlotinib

Total 2679 results

Weill Medical College of Cornell University
OSI Pharmaceuticals

Completed

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

Carcinoma, Non-small Cell Lung

United States
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Korea, Republic of, Taiwan, Thailand
Baohui Han

Completed

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation. (ML25444)

Non Small Cell Lung Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

Head and Neck Cancer

Spain, United States
Hoffmann-La Roche

Completed

A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Austria
Hoffmann-La Roche

Completed

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy (TIME)

Non-Squamous Non-Small Cell Lung Cancer

Belgium
Memorial Sloan Kettering Cancer Center

Terminated

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Lung Cancer

United States
Li Zhang

Unknown

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

Non-small Cell Lung Cancer

China
Rigshospitalet, Denmark
Hoffmann-La Roche

Terminated

Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy

Non Small Cell Lung Cancer

Denmark
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Second Affiliated Hospital...

Unknown

Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Lung, Carcinoma
National Cancer Institute (NCI)
NCIC Clinical Trials Group

Completed

Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer

Canada
Mayo Clinic
Genentech, Inc.

Completed

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Cholangiocarcinoma | Primary Sclerosing Cholangitis | Chemoprevention | Trisomy 7

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer

United States, Canada
Grupo Gallego de Investigaciones Oncologicas

Completed

Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients (XELTA)

Metastatic Adenocarcinoma of the Pancreas

Spain
Pfizer

Completed

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

Acne Inversa

United States, Australia, Canada
Pfizer

Recruiting

A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

Renal Impairment

United States
Pfizer

Completed

A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.

Healthy

Belgium
Pfizer

Completed

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Overweight and/or Obesity

Belgium
Shire

Completed

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease (OPERA)

Crohn's Disease

Korea, Republic of, United States, Spain, Japan, Serbia, Germany, Belgium, Netherlands, Poland, Austria, Bulgaria, Canada, France, Norway, Slovakia, South Africa
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteers

United States
Pfizer

Completed

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States, Belgium, Czechia, Slovakia
Pfizer

Completed

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, United States
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Attention Deficit Hyperactivity Disorder

United States
Pfizer

Completed

Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion

Healthy

Belgium
Pfizer

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

Pain | Migraine Disorders

United States
Pfizer

Withdrawn

A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Obesity
Pfizer

Completed

A Study Of PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

Healthy Volunteers

Belgium
Pfizer

Terminated

Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845

Healthy Volunteers

United States
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; National Comprehensive Cancer Network

Completed

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Breast Cancer

United States
Sun Yat-sen University

Active, not recruiting

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Pfizer

Completed

A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects (B538-05)

Healthy Subjects

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Guangdong Association of Clinical Trials

Not yet recruiting

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Carcinoma, Non-Small-Cell Lung | Brain Metastases | Leptomeningeal Metastasis

China
Pfizer

Active, not recruiting

A Study to Learn How Different Amounts and Forms of the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults

Healthy Participants

Belgium
Basilea Pharmaceutica

Active, not recruiting

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction.

Hepatic Impairment

United States
Pfizer

Active, not recruiting

A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States, Poland, Germany
Pfizer

Completed

A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults

Healthy Participants

Belgium
Pfizer

Completed

A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers

Healthy

Belgium
Pfizer

Completed

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

SARS-CoV-2 Infection

United States
Pfizer

Completed

Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis

Rheumatoid Arthritis | Systemic Lupus Erythematosus

United States
Pfizer

Completed

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Grupo Espanol de trasplantes hematopoyeticos y...

Active, not recruiting

Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease

Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)

Spain
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Yale University

Completed

Cannabinoid Augmentation of Fear Response in Humans

Fear Conditioning

United States
Pfizer

Terminated

Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants

Healthy

Belgium
Biogen

Completed

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD)

Schizophrenia

United States

3

Subscribe